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Abstract
The synthesis of phosphonate analogues of ribose-1-phosphate and 5-fluoro-5-deoxyribose-1-phosphate is described. Preparations
of both the α- and β-phosphonate anomers are reported for the ribose and 5-fluoro-5-deoxyribose series and a synthesis of the
corresponding cyclic phostones of each α-ribose is also reported. These compounds have been prepared as tools to probe the details
of fluorometabolism in S. cattleya.
Introduction
Fluoroacetate  (1)  and  4-fluorothreonine  (2)  are  unusual
secondary metabolites in that they contain a fluorine atom. They
are elaborated by the bacterium Streptomyces cattleya as part of
its defense strategy since 4-fluorothreonine (2) has antibiotic
activity and fluoroacetate (1) is a toxin [1]. The biosynthetic
pathway from fluoride ion to these fluorometabolites has largely
been elucidated and is summarised in Scheme 1 [2].
The first committed step in the biosynthesis involves the fluor-
inase, an enzyme that catalyses nucleophilic attack of fluoride
ion on SAM (3) to generate 5′-FDA (4). The initial fluorinated
product 5′-FDA (4) is then depurinated by a purine nucleotide
phosphorylase (PNP) to give 5-fluoro-5-deoxyribose-1-phos-
phate (5). This phosphate intermediate becomes the substrate
for a ring opening isomerisation reaction converting 5-fluoro-5-
deoxyribose-1-phosphate (5)  to 5-fluoro-5-deoxyribulose-1-
phosphate (6). Further processing to fluoroacetaldehyde (7) and
then conversion to fluoroacetate (1) and 4-fluorothreonine (2)
complete  the  pathway.  The  focus  of  this  research  involved
generating  a  potential  inhibitor  of  either  the  PNP  or  the
subsequent isomerase enzymes as a tool, to try to accumulate
biosynthesis intermediates in cell free extract studies [3]. We
have already demonstrated that the S. cattleya PNP can depur-
inate  both  5′-FDA and adenosine,  and thus  the  presence  or
absence of fluorine at the C-5′-position is not a requisite for
catalysis.  The  next  enzymatic  step  involves  a  ring  opening
isomerisation of  the  ribose-1-phosphate  5.  In  this  paper  we
report the synthesis of phosphonate analogues 8 and 9 of ribose-
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Scheme 1: Biosynthetic pathway from fluoride ion to fluoroacetate 1 and 4-fluorothreonine 2 in S. cattleya [2].
1-phosphate 5  where the linking phosphate oxygen has been
replaced by a methylene group and for 9 the fluorine has been
replaced  by  OH  (see  Figure  1).  These  phosphonates  were
considered as candidate inhibitors for either the PNP or the
isomerase enzyme, with potential utility as tools to interrogate
the  biosynthesis  system,  and  as  inert  candidate  substrate
analogues for enzyme co-crystallisation studies. We also report
the  synthesis  of  the  cyclic  phostone  analogues  10  and  11
(Figure  1),  which  were  viewed  also  as  potential  substrate
analogues for co-crystallisation studies, particularly with the
isomerase enzyme which converts 5  to 6  during the biosyn-
thesis.
Figure 1: Synthesized phosphonates 8 and 9 and cyclic phostones 10
and 11.
Results and Discussion
The target phosphonates 8 and 9 have been prepared by routes
A and B as shown in Scheme 1 and Scheme 2 respectively. The
routes start either from D-ribonic-γ-lactone (12) or D-ribose
(13).  For  each  route  the  key  synthetic  steps  are  the  same
involving installation of the dimethyl phosphonate moiety on a
2,3-O-isopropylidene ribofuranoside via a Wadsworth-Emmons
reaction [4]. Route A (Scheme 2) started with acetonide protec-
tion of D-ribonic-γ-lactone (12) to generate 2,3-isopropylidene
14 [5]. Fluorination of the free 5-hydroxyl group with Deoxo-
fluor™ [6]  gave 5-deoxy-5-fluoro-2,3-O-isopropylidene-D-
ribonic-γ-lactone (15) in good yield and then subsequent reduc-
tion of lactone 15 with NaBH4 resulted in the fully reduced diol
16. Diol 16 has been previously synthesised [7], however this
route appears to offer a more efficient preparation. In our case,
even with limiting NaBH4, mixtures of diol 16 and 5-deoxy-5-
fluoro-2,3-ribofuranoside 17 were obtained, however treatment
with  DIBAL-H  at  40  °C  [8]  gave  a  clean  reaction  and
5-fluororibofuranoside 17  was recovered in  moderate  yield.
Finally a Wadsworth-Emmons reaction [4] of 17 using tetra-
methyl  methylenediphosphonate  in  DCM/aq.  NaOH gave  a
smooth conversion to 5-fluorophosphonate 18 which had an α:β
ratio of 3.2:1. (The major α-anomer was assigned for 18 based
on the subsequent NMR assignments of 23a and b, see below.)
These diastereoisomers were inseparable by conventional chro-
matography.
Due  to  the  inability  to  separate  α−18  from  β−18,  route  B
(Scheme  3)  was  explored  as  an  alternative.  Following  the
protocol demonstrated by Meyer et al. [4], 5-O-trityl-phosphon-
ates  21a  and 21b  were obtained as  individual  epimers after
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Scheme 2: Synthetic route A. Reagents and conditions: a) acetone, concd H2SO4 (cat.), 6 h, 86%; b) Deoxo-fluor™, DCM, 40 °C, 30 min, 84%; c)
NaBH4, ethanol, 0 °C, 2 h, 65%; d) DIBAL-H, toluene, 40 °C, 64%; e) CH2[P(O)(OMe)2]2, DCM, 50% aq NaOH, 60%.
Scheme 3: Synthetic route B. Reagents and conditions: a) acetone, concd H2SO4 (cat.), 4 h, 90%; b) TrCl, pyridine, DMAP, rt, 16 h, 94%; c)
CH2[P(O)(OMe)2]2, 50% aq NaOH; DCM, 64%; d) anhyd ZnCl2, DCM, rt, 2 h, 78–81%; e) TsF, TBAF, THF, reflux, 16 h, 83–92%; f) i) TMSBr, DCM,
rt; ii) TFA:H2O (1:1), iii) cyclohexylamine, pH ~11, 84–87%; g) i) TMSBr, DCM, rt; ii) TFA:H2O (1:1), iii) Ac2O, pyridine, 16 h, 40–47%.
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Figure 2: X-Ray crystal structure of cyclohexylammonium salt 8a.
chromatographic separation of the initial product mixture (α:β
of 4:1). Detritylation of 21a, b was accomplished with ZnCl2
[9] to generate the 5-hydroxyphosphonates 22a and 22b in a
good yield. The free alcohol of both epimers was then fluorin-
ated at the 5-position using tosylfluoride and TBAF in refluxing
THF [10,11].  Sequential  deprotection  of  23a  and  23b  with
TMSBr and then TFA yielded the free phosphonic acids which
were neutralised with cyclohexylamine [12] to generate the
non-hygroscopic salts 8a, b and 9a, b which could be recrystal-
lised from MeOH/acetone. X-Ray structure analysis of a suit-
able crystal of the fluoromethyl phosphonate 8a was obtained
(Figure 2) which confirmed its structure and stereochemical
relationship to intermediate ribose-1-phosphate metabolite 5.
Clearly, phosphonate 8a formed a 1:1 salt with the amine. Addi-
tionally, 23a and 22a were treated in separate reactions with
acetic  anhydride in  dry pyridine [13]  to  generate  the cyclic
phostones 10 and 11 respectively. In each case this conversion
could be conveniently followed by a change in the 31P-NMR
resonance of 27 ppm (phosphonate) to 44 ppm, characteristic of
a cyclic phostone. Purification by chromatography allowed the
recovery of the phostones 10 and 11 in moderate yield.
Incubation  of  the  phosphonate  salts  8a  and  9a  with  the  S.
cattleya PNP did not result in an inhibitory effect, and clearly
the phosphonates are not good substrate analogues of the phos-
phates with this enzyme. We are currently exploring phosphon-
ates 8a and 9a as inhibitors of the isomerase, the next enzyme
on the pathway, and in order to probe the molecular mechanism
of this enzyme, these phosphonates and the phostones 10 and 11
are being used in co-crystallisation trials with each of the over-
expressed enzymes (PNP and isomerase).
Experimental
Nuclear  magnetic  resonance  (NMR)  spectra  were  obtained
using Bruker Advance 300 and Bruker Advance II  400.  All
chemical shifts (δ) are reported in parts per million (ppm) and
coupling constants (J) are given in Hertz (Hz). Melting points
were  determined  in  Pyrex  capillaries  using  a  Gallenkamp
Griffin MPA350.BM2.5 melting point apparatus. Infra red (IR)
spectra were recorded on Nicolet Avatar 360 FT-IR. High resol-
ution  mass  spectrometry  (HRMS)  was  carried  out  using  a
Micromass  LCT (Manchester,  UK) mass  spectrometer  with
electrospray ionization (ESI) operating in positive and negative
modes. Optical rotations were measured on Perkin-Elmer model
341 polarimeter.
5-Deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-1,4-lactone
(15). Deoxo-Fluor™ (3.06 cm3, 16.58 mmol) was slowly added
to  a  stirred  solution  of  2,3-O-isopropylidene-D-ribono-1,4-
lactone 14 [5] (1.04 g, 5.53 mmol) in DCM (10 cm3) at ambient
temperature. After stirring at 40 °C for 30 min, the reaction
mixture was cooled down to ambient temperature and silica gel
(0.5 g) was carefully added. After removal of solvent, silica gel
was applied to a silica gel column eluting with EtOAc:hexane
(1:3) to afford 15 as a white solid (0.88 g, 84%); mp: 60–62 °C;
[α]20D:  −82.8°  (c  5.0  × 10−3,  CHCl3);  1H NMR (400 MHz;
CDCl3): δ = 1.39 (s, 3H, CH3), 1.48 (s, 3H, CH3), 4.67 (ddd,
1H, 3JHH = 1.9, 2JHH = 11.0, 2JHF = 46.1, H-5), 4.72 (dddd, 1H,
3JHH = 1.7, 3JHH = 1.7, 3JHH = 1.7, 3JHF = 34.57, H-4), 4.74
(ddd, 1H, 3JHH = 1.8, 2JHH = 11.0, 2JHF = 48.1, H-5), 4.81 (dd,
1H, 3JHH = 3.3, 3JHH = 5.6, H-3), 4.85 (d, 1H, 3JHH = 5.7, H-2).
13C NMR (100 MHz; CDCl3): δ = 25.5 (CH3), 26.8 (CH3), 75.1
(d, 4JCF = 3.9, C-2), 77.2 (d, 3JCF = 5.1, C-3), 80.3 (d, 2JCF =
19.2, C-4), 82.2 (d, 1JCF = 171.3, C-5), 113.9 (C(CH3)2), 173.6
(C-1). 19F NMR (282 MHz, CDCl3): δ = −236.0 (ddd, 3JHF =
3.3, 2JHF = 34.8, 2JHF = 46.3). νmax (KBr): 3563, 2993, 1804,
1455, 1384, 1272, 1054, 849, 610, 513. HRMS (ES+): Calcd.
for C8H11FO4Na [M+Na]+: 213.0539, found: 213.0537.
5-Deoxy-5-fluoro-2,3-O-isopropylidene-D-ribofuranose (17).
A solution of DIBAL-H (1 M in hexane, 2.20 ml, 2.18 mmol)
was carefully added to a solution of 5-deoxy-5-fluoro-2,3-O-
isopropylidene-D-ribono-1,4-lactone (15) (0.42 g, 2.18 mmol)
in dry toluene (10 ml) at 40 °C and the reaction was monitored
by 19F NMR. After completion, MeOH (2 ml) was added. The
slurry gel was broken by adding sat.  aq.  solution of sodium
potassium tartrate (1 ml). After extracted into ether (3 × 10 ml),
the combined organic phases were washed with brine and dried
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over MgSO4. After removal of solvent under reduced pressure
the  residue  was  purified  over  silica  gel  eluting  with  60%
EtOAc/hexane to afford 17 as colourless oil (0.26 g, α/β = 7.6/1,
63.6%) and 16  (25.4  mg,  6.0%).  α-anomer:  1H NMR (300
MHz; CDCl3): δ = 1.27 (s, CH3), 1.43 (s, CH3), 3.27 (t, 3JHH =
5.17, -OH), 4.31–4.41 (m, 2H, H-4, H-5, (overlap with β, H-4,
H-5)), 4.44–4.61 (m, 2H, H-3, H-5 (overlap with β, H-3, H-5)),
4.71 (d, 3JHH = 5.9, H-2), 5.38 (dd, 1H, 3JHH = 2.5, 3JHH = 5.3,
H-1). 13C NMR (75 MHz; CDCl3): δ = 24.9 (CH3), 26.5 (CH3),
81.2 (d, 3JCF = 5.5, C-4), 82.2 (d, 1J = 171.3, C-5), 84.8 (C-3 or
C-2),  86.1 (C-2 or  C-3),  103.3 (C-1),  112.7 (C(CH3)2).  19F
NMR (282 MHz, CDCl3): δ = −230.8 (dddd, 4JHF = 3.3, 3JHF =
37.5, 2JHF = 47.3, 2JHF = 47.3, 1F). β-anomer: 1H NMR (300
MHz; CDCl3): δ = 1.50 (s, CH3), 1.33 (s, CH3), 3.93 (d, 3JHH =
10.9, -OH), 4.31–4.41 (m, 2H, H-4, H-5, (overlap with α, H-4,
H-5)), 4.44–4.61 (m, 2H, H-3, H-5 (overlap with α, H-3, H-5)),
4.74 (ddd, 1H, 3JHH = 0.8, 3JHH = 1.5, 3JHH = 6.4, H-4), 5.33
(ddd, 1H, 3JHH = 3.7, 3JHH = 3.7, 3JHH = 10.9, H-1). 13C NMR
(75 MHz; CDCl3): δ = 24.7 (CH3), 26.1 (CH3), 79.5 (C-2), 79.6
(d, 2JCF = 17.8, C-4), 80.7 (d, 3JCF = 6.7, C-3), 85.1 (d, 1J =
170.5, C-5), 97.7 (C-1), 114.2 (C(CH3)2). 19F NMR (282 MHz,
CDCl3):  δ = −225.4 (dddd, 4JHF  = 3.2,  3JHF  = 23.1,  2JHF  =
46.5, 2JHF  = 46.5, 1F). νmax  (neat): 3426, 2944, 1376, 1211,
1072,  868,  504.  HRMS  (ES+):  Calcd.  for  C8H13FO4Na
[M+Na]+:  215.0696,  found:  215.0691.
D-allo,altro-2,5-Anhydro-1-deoxy-1-(dimethoxyphosphinyl)-
6-fluoro-3,4-O-isopropylidenehexitol (18). 50% aq Solution
NaOH (3 ml) was slowly added to a vigorously stirring mixture
of 5-deoxy-5-fluoro-2,3-O-isopropylidene-D-ribofuranose 17
(0.125 g, 0.63 mmol) and tetramethyl methylenediphosphonate
(0.16 g, 0.69 mmol) in DCM (3 ml) at ambient temperature.
After 18 h, the reaction mixture was diluted with DCM (10 ml)
and the aq phase was extracted with DCM (2 × 10 ml). The
combined organic phases were dried over MgSO4, and filtered.
After removal of solvent, the residue was purified over silica
gel eluting with 5% MeOH:DCM to afford a mixture of epimers
18 as colourless oil (0.11 g, α/β = 3.2/1, 58.5%).1H NMR (400
MHz; CDCl3): δ = 1.19 (C(CH3)2), 1.33 (C(CH3)2), 1.95–2.20
(m, 2H, H-1), 3.58–3.63 (m, POCH3), 3.95–4.69 (m, 6H). 13C
NMR (162 MHz; CDCl3): δ = 30.3–31.1 (m, Pα), 31.7–32.4 (m,
Pβ). 19F NMR (282 MHz, CDCl3): δ = −231.1 (ddd, 3J = 28.90,
2J  = 47.32,  2J  = 47.32,  1Fα),  −229.3 (dddd,  4J  = 2.26,  3J  =
32.94, 2J = 47.29, 2J = 47.29, 1Fβ). νmax (neat): 3466, 2955,
1644, 1459, 1374, 1213, 1023, 822, 537. HRMS (ES+): Calcd.
for C11H20O4FPNa [M+Na]+: 321.0879, found: 321.0874.
D-altro-2,5-Anhydro-1-deoxy-1-(dimethoxyphosphinyl)-6-
fluoro-3,4-O-isopropylidenehexitol (23a). A solution of TBAF
(1 M in THF, 2.16 ml, 2.16 mmol) was added to a mixture of
22a (0.16 g, 0.54 mmol) and TsF (0.28g, 1.62 mmol) in THF
(15 ml) and then the reaction mixture was brought to reflux.
After refluxing for 18 h, the reaction mixture was cooled down
to ambient temperature and then filtered through a shot pad of
silica gel washing with EtOAc. After removal of solvent the
residue was purified over silica gel eluting with MeOH:DCM
(1:20) to afford 23a as colourless oil (0.148 g, 92.3%). [α]D20:
−16.44° (c 2.25 × 10−3, CHCl3). 1H NMR (300 MHz; CDCl3):
δ = 1.28 (s, 3H, C(CH3)2). 1.42 (s, 3H, C(CH3)2), 2.13 (ddd,
1H, 3JHH = 6.7, 2JHH = 15.4, 2JHP = 18.1, H-1), 2.23 (ddd, 1H,
3JHH = 6.6, 2JHH = 15.4, 2JHP = 18.4, H-1), 3.68 (d, 3H, 3JHH =
3.9, POCH3), 3.70 (d, 3H, 3JHH = 3.9, POCH3), 4.12 (ddd, 1H,
3JHH = 2.9, 3JHH = 2.9, 3JHF = 33.1, H-5), 4.26 (dddd, 1H, 3JHH
= 3.2, 3JHH = 6.6, 3JHH = 6.6, 3JHP = 10.3, H-2), 4.44 (ddd, 1H,
3JHH = 3.4, 2JHH = 10.2, 2JHF = 46.8, H-5), 4.48 (ddd, 1H, 3JHH
= 3.2, 2JHH  = 10.2, 2JHF  = 47.6, H-5), 4.65 (dd, 3JHH  = 3.9,
3JHH = 6.0, 1H, H-3), 4.77 (d, 3JHH = 6.0, 1H, H-4). 13C NMR
(75 MHz; CDCl3): δ = 24.9 (CH3), 25.5 (d, 2JPC = 141.9, C-1),
26.2 (CH3), 52.3 (d, 2JPC = 6.4, POCH3), 52.6 (d, 2JPC = 6.2,
POCH3), 76.9 (d, 2JCF = 1.9, C-2), 81.7 (d, 2JPC = 7.5, C-3),
82.1 (d, 2JCF = 6.4, C-4), 82.5 (d, 2JCF = 17.8, C-5), 84.8 (d,
1JCF  =  172.4,  C-6),  112.7 (C(CH3)2).  31P NMR (121 MHz;
CDCl3): δ = 31.65–32.38 (m, P). 19F NMR (282 MHz; CDCl3)
−229.3 (ddd, 3JHF = 2.2, 3JHF = 33.2, 2JHF = 33.2, 2JHF = 47.1,
1F).  νmax  (neat):  2954,  1372,  1209,  1025,  819,  503.  HRMS
(ES+): Calcd. for C11H20O4FPNa [M+Na]+: 321.0879, found:
321.0879.
D-allo-2,5-Anhydro-1-deoxy-1-(dimethoxyphosphinyl)-6-
fluoro-3,4-O-isopropylidenehexitol  (23b).  The  same
procedure as described for 23a was repeated with 22b (70 mg,
0.23 mmol) to afford 23b as a colourless oil (60 mg, 83.1%).
[α]D20: −18.78° (c 2.45 × 10−3, CHCl3), 1H NMR (300 MHz;
CDCl3): δ = 4.64 (dd, 3JHH = 3.9, 3JHH = 6.6, 1H, H-4), 4.49
(ddd, 1H, 3JHH = 2.8, 2JHH = 10.4, 2JHF = 47.6, H-6), 4.48 (dd,
1H, 3JHH = 4.3, 3JHH = 6.6, H-3), 4.45 (ddd, 1H, 3JHH = 3.5,
2JHH = 10.8, 2JHF = 47.0, H-6), 4.23 (dddd, 1H, 3JHH = 4.2,
3JHH = 6.7, 3JHH = 6.7, 3JHP = 11.1, H-2), 4.09 (ddd, 1H, 3JHH
= 3.4, 3JHH = 3.4, 2JHF = 28.3, H-5), 3.71 (d, 3H, 3JHH = 2.2,
POCH3), 3.67 (d, 3H, 3JHH = 2.3, POCH3), 2.09 (d, 1H, 2JHP =
18.4, H-1), 2.13 (dd, 1H, 3JHH = 0.9, 2JHP = 18.4, H-1), 1.47 (s,
3H,  C(CH3)2),  1.28  (s,  3H,  C(CH3)2).  13C NMR (75  MHz;
CDCl3):  δ = 25.9 (CH3),  27.7 (CH3),  30.1 (d,  2JCP  = 141.1,
C-1), 52.7 (d, 2JCP = 6.5, OCH3), 52.9 (d, 2JCP = 6.5, OCH3),
80.5 (d, 2JCF = 3.4, C-2), 81.2 (d, 3JCF = 7.4, C-4), 83.2 (d, 2JCF
= 172.7, C-6), 83.5 (d, 2JCF = 18.3, C-5), 85.7 (d, 4JCF = 11.3,
C-3),  114.9  (C(CH3)2).  31P  NMR (162  MHz;  CDCl3):  δ  =
30.33−31.09 (m, P). 19F NMR (282 MHz; CDCl3): δ = −231.0
(ddd, 3JHF = 28.8, 2JHF = 47.3, 2JHF = 47.3, 1F). νmax (neat):
3464, 2956, 1383, 1214, 1030, 822, 513. HRMS (ES+): Calcd.
for C11H20O4FPNa [M+Na]+: 321.0879, found: 321.0875.
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Cyclohexylammonium salt 8a. TMSBr (0.18 ml, 1.36 mmol)
was added to a solution of 23a (94.8 mg, 0.34 mmol) in DCM
(5 ml). The progress of reaction was monitored by 31P NMR.
The disappearing of signal at 31.5–32.1.0 ppm indicating that
the reaction was gone completion. A solution of TFA:H2O (1:1,
1 ml) was then added to the mixture. After 30 min, water (5 ml)
was added, the solvents were removed under reduced pressure.
To this residue was added water (5 ml) and the solvent was
removed under reduced pressure;  this was repeated until  all
trace of TFA was gone. To this residue 5 ml of water was added
and adjusted to pH 11 with cyclohexylamine. After removal of
solvent,  the  residue  was  dissolved  in  EtOH  and  about  0.5
volume of acetone was added. The precipitate was filtered off to
afford 8a as colourless needles (97.6 mg, 87.2%). Mp. 168–170
°C, [α]D20:  +18.67° (c  1.50 × 10−3,  MeOH),  1H NMR (400
MHz;  MeOH-d4):  δ  =  1.07–1.16  (m,  1H,  cyclohexyl),
1.19–1.34 (m, 4H, cyclohexyl), 1.57–1.64 (m, 1H, cyclohexyl),
1.70–1.79 (m, 2H, cyclohexyl), 1.88–1.94 (m, 2H, cyclohexyl),
1.87 (ddd, 1H, 3JHH = 4.9, 2JHH = 10.1, 2JHP = 19.1, H-1), 2.04
(ddd,  1H,  3JHH  =  10.1,  2JHH  =  14.2,  2JHP  =  17.1,  H-1),
2.91–2.98 (m, 1H, H-1, cyclohexyl), 3.83 (dddd, 1H, 3JHH =
2.0, 3JHH = 4.6, 3JHH = 8.7, 3JHF = 25.5, H-5), 4.01 (dd, 1H,
3JHH  = 4.6, 3JHH  = 8.7, H-4), 4.10–4.14 (br, 1H, H-3), 4.17
(dddd,  1H, 3JHH  = 2.9,  3JHH  = 4.5,  3JHH  = 4.5,  3JHP  = 9.7,
H-2),  4.34 (ddd,  1H, 3JHH  = 4.7,  2JHH  = 10.3,  2JHF  = 47.7,
H-6),  4.56 (ddd,  1H, 3JHH  = 2.1,  2JHH  = 10.3,  2JHF  = 48.4,
H-6). 13C NMR (100 MHz; MeOH-d4): δ = 25.4 (2 × C, cyclo-
hexyl), 25.9 (C, cyclohexyl), 31.2 (d, 1JCP = 129.5, C-1), 31.9
(2 × C, cyclohexyl), 51.5 (C-1, cyclohexyl), 72.9 (d, 3JCF = 7.9,
C-4), 73.4 (C-3), 79.7 (d, 2JCP = 2.7, C-2), 81.0 (d, 2JCF = 17.6,
C-5), 84.3 (d, 1JCF = 170.9, C-6). 31P NMR (162 MHz; MeOH-
d4): δ = 18.7 (ddd, 3JHP = 2.9, 2JHP = 18.1, 2JHP = 18.1 ). 19F
NMR (376 MHz; MeOH-d4):  δ = −232.4 (ddd, 3JHF  = 25.5,
2JHF = 47.4, 2JHF = 47.4, 1F). νmax (KBr): 3199, 2939, 2720,
2012, 1597, 1429, 1389, 1121, 1018, 925. HRMS (ES+): Calcd.
for C12H26NO6FP [M+H]+: 330.1482, found: 330.1492.
Cyclohexylammonium  salt  8b.  The  same  procedure  as
described for preparation of 8a was repeated with 23b (53.1 mg,
0.19 mmol) to afford 8b as white solid (52.1 mg, 83.3%). Mp.
146–148 °C, [α]D20: +3.09° (c 3.55 × 10−3, MeOH), 1H NMR
(400 MHz;  MeOH-d4):  δ  =  1.05–1.32  (m,  5H,  cyclohexyl),
1.54–1.74  (m,  5H,  1H-1  overlap  with  4H-cyclohexyl),
1.87–1.90 (m, 2H, cyclohexyl), 1.99 (ddd, 1H, 3JHH = 3.7, 2JHH
= 14.1, 2JHP = 18.8, H-1), 2.83–2.91 (m, 1H, H-1, cyclohexyl),
3.96 (t, 3JHH = 6.3, H-3), 3.83 (dddd, 1H, 3JHH = 3.7, 3JHH =
3.7, 3JHH = 3.7, 3JHF = 25.9, H-5), 3.97 (dd, 1H, 3JHH = 3.9,
3JHH = 5.5, H-4), 3.95–4.01 (m, 1H, H-2), 4.31 (ddd, 1H, 3JHH
= 4.1, 2JHH = 10.2, 2JHF = 47.4, H-6), 4.36 (ddd, 1H, 3JHH =
3.2,  2JHH  =  10.2,  2JHF  =  47.9,  H-6).  13C NMR (100  MHz;
MeOH-d4): δ = 25.5 (2 × C, clohexyl), 26.1 (C, cyclohexyl),
32.8 (2 × C, clohexyl), 35.9 (d, 1JCP = 127.0, C-1), 51.4 (C-1,
cyclohexyl), 73.1 (d, 3JCF = 5.1, C-4), 77.4 (C-3), 80.7 (d, 2JCP
= 2.6, C-2), 84.1 (d, 2JCF = 18.5, C-5), 84.3 (d, 1JCF = 170.5,
C-6). 31P NMR (162 MHz; MeOH-d4): δ = 17.9 (ddd, 3JHP =
3.9, 2JHP = 17.8, 2JHP = 17.8 ). 19F NMR (376 MHz; MeOH-
d4):  δ  = −231.6 (ddd,  1F,  3JHF  = 25.6,  2JHF  = 47.7,  2JHF  =
47.7). νmax (KBr): 3436, 2937, 2561, 2012, 1618, 1454, 1389,
1051, 974. HRMS (ES+): Calcd. for C12H26NO6FP [M+H]+:
330.1482, found: 330.1485.
Fluoromethylphostone 10
Deprotection as described for 8a was repeated with 23a (80 mg,
0.27  mmol)  in  DCM  (5  ml).  Without  addition  of  cyclo-
hexylamine, the residue was dissolved in dry pyridine (1 ml)
and acetic anhydride (0.04 ml, 0.4 mmol) was then added. The
emergence of an 31P-NMR signal at 45 ppm and a disappear-
ance of signal at 27 ppm indicated that the reaction had gone
completion. After removal of the solvent under reduced pres-
sure,  the  crude  was  purified  over  silica  gel  eluting  with
MeOH:DCM (3:2) to afford 10 as white solid (23 mg, 40.2%).
Mp. 180−182 °C, [α]D20: +103.0° (c 1.0 × 10−3, MeOH). 1H
NMR (300 MHz; MeOH-d4): δ = 1.73–1.98 (m, 2H, H-1), 4.25
(dddd,  1H,  3JHH  =  2.10,  3JHH  =  3.90,  3JHH  =  8.30,  3JHF  =
26.32, H-1, H-5), 4.36 (ddd, 1H, 3JHH = 3.90, 2JHH = 10.63,
2JHF = 47.18, H-6), 4.48 (ddd, 1H, 3JHH = 2.10, 2JHH = 10.63,
2JHF = 48.14, H-6), 4.67–4.71 (m, 1H, H-3), 4.72–4.82 (m, 1H,
H-2), 4.88 (ddd, 1H, 3JHH = 1.91, 3JHH = 4.61, 3JHP = 8.34,
H-4).  13C NMR (75  MHz;  MeOH-d4):  δ  =  29.6  (d,  1JCP  =
119.5, C-1),  74.4 (d,  4JCF  = 7.15, C-4),  77.8 (d,  4JCF  = 8.8,
C-3), 79.5 (d, 3JCF = 18.36, C-5), 81.2 (d, 2JCP = 4.0, C-2), 83.2
(d, 1JCF = 172.1, C-6). 19F NMR (282 MHz; MeOH-d4): δ =
−234.3 (ddd, 1F, 3JHF = 26.4, 2JHF = 47.4, 2JHF = 47.7). 31P
NMR  (162  MHz;  MeOH-d4):  δ  =  41.9–42.6  (br,  m).  νmax
(PTFE): 3419, 1214, 1154, 799, 503. HRMS (ES-): Calcd. for
C6H9FO5P [M-H]: 211.0172, found: 211.0166.
Supporting Information
The experimental and analytical data for compounds 9b,
11, 14, 16, and 19–22 are provided in the supporting
information.
Supporting Information File 1
Experimental.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-5-37-S1.doc]
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